Abstract Using a model of established malignancy, we found that cyclophosphamide (Cy), administered at a dose not requiring hematopoietic stem cell support, is superior to low-dose total body irradiation in augmenting antitumor immunity. We observed that Cy administration resulted in expansion of tumor antigen-speciWc T cells and transient depletion of CD4 + Foxp3 + regulatory T cells (Tregs). The antitumor eYcacy of Cy was not improved by administration of anti-CD25 monoclonal antibody given to induce more profound Treg depletion. We found that Cy, through its myelosuppressive action, induced rebound myelopoiesis and perturbed dendritic cell (DC) homeostasis. The resulting DC turnover led to the emergence of tumor-inWltrating DCs that secreted more IL-12 and less IL-10 compared to those from untreated tumor-bearing animals. These newly recruited DCs, originating from proliferating early DC progenitors, were fully capable of priming T cell responses and ineVective in inducing expansion of Tregs. Together, our results show that Cy-mediated antitumor eVects extend beyond the welldocumented cytotoxicity and lymphodepletion and include resetting the DC homeostasis, thus providing an excellent platform for integration with other immunotherapeutic strategies.
Introduction
In recent years, several studies have suggested that chemotherapy and radiotherapy administered in nonmyeloablative doses may augment the host's immune response to malignancy, especially if given in sequence with other immunotherapeutic modalities [1, 2] . This eVect is thought to be a consequence of chemoradiotherapy-mediated enhanced tumor-cell apoptosis and cross-presentation of tumor antigens [3, 4] , elimination of cytokine sinks [5] , augmented homeostasis-driven expansion of tumor-induced or adoptively transferred tumor-speciWc CD8 + T cells [6, 7] , depletion of regulatory T cells (Tregs) [7] [8] [9] , and destruction of tumor stroma [10] . Use of myeloablative irradiation as a platform for adoptive transfer of tumor-speciWc T cells has also provided insight into additional mechanisms that can augment antitumor activity. First, irradiation-induced tissue injury associated with release of high levels of proinXammatory cytokines and translocation of bacteria-derived LPS into bloodstream provides a milieu that is optimal for in vivo activation of dendritic cells (DCs) [11] . Second, puriWed hematopoietic stem cells (HSCs) given primarily to rescue myeloablated host can directly stimulate expansion of adoptively transferred T cells [12] . This eVect is presumably related to the ability of transferred Lin ¡ CD117 + HSCs to rapidly diVerentiate into antigen-presenting cells (APCs) in vivo. Recent study showed comparable antitumor beneWts of nonmyeloablative and myeloablative conditioning with total body irradiation (TBI) as a platform for adoptive cell therapy [13] . We hypothesized that alternative strategy which could bypass the obstacles of high toxicity and complexity of ex vivo cell manipulation, while relying on the same mechanisms in augmenting antitumor immunity would be advantageous for clinical translation. Cyclophosphamide (Cy) is diVerent from majority of other chemotherapeutic agents in that it can be repeatedly administered in very high doses without the need for HSC rescue due to the lack of toxicity to stem cells [14, 15] . Cy treatment is known to modulate both adaptive and innate immunity. On the T cell side, Cy administration induces transient lymphopenia that is associated with augmented in vivo proliferation and expansion of antigen-speciWc T cells [16] , reduction in the number of Tregs [7, 9, 17] , and augmented function of tumor-inWltrating T cells in the tumor stroma [18] . Cy eVects on the innate immunity are manifested through increased levels of type I IFN and other proinXammatory cytokines in serum [16, 19] and by elevated number and activation status of CD11b + myeloid cells in vivo [16, 20, 21] . We thus sought to further examine the mechanisms of Cy-augmented antitumor immunity, particularly those pertaining to T cell-DC interaction in vivo.
Here, using a model of advanced metastatic disease, we report that Cy administration provides strong antitumor eVect resulting in survival of approximately 40% of animals. We found that, despite Cy's well-described eVects on Treg elimination, Tregs recover rapidly and further attempts to prolong their depletion yield no additional beneWt. We found that Cy's eVect of inducing reversal of systemic and in situ DC paralysis in the tumor-bearing hosts and its ability to mobilize early proliferating DC progenitors are crucial mechanisms for enhancing antitumor immunity.
Materials and methods

Animals
BALB/cAnNCr (BALB/c; H-2 d , CD45.2) and C57BL/6 (B6; H-2 b ) mice were purchased from NCI (Frederick, MD, USA). BALB/c-CD45.1 and BALB/c-Ifng tm1Ts (IFN-KO ) mice were maintained in a pathogen-free facility and were 6-8 weeks old at the time of experiments. All experiments were performed in accordance with protocols approved by the Animal Care and Use Committee of the Johns Hopkins University.
Cell lines and tumor model CT26 colon carcinoma (H-2 d ) cell line was maintained as previously described [22, 23] . For tumor implantation, we employed the model of hemispleen injection previously described [23] . On day 13 after tumor implantation, animals were injected intraperitoneally with 200 mg/kg of cyclophosphamide (Bristol-Myers Squibb, Evansville, IN, USA). In designated experiments animals were irradiated with 200 cGy on day 10 post-tumor implantation. For in vivo CD4, CD8, or CD25 depletion, tumor-bearing animals were injected intraperitoneally with designated monoclonal antibodies (mAbs) or corresponding isotype control at a dose and schedule indicated for each individual experiment. Following clones were used: GK1.5 (anti-CD4), 2.43 (anti-CD8), and PC61 (anti-CD25). All antibodies were obtained from BioXcell, West Lebanon, NH, USA. On day 16, posttumor implantation a tumor vaccine comprised of irradiated (5,000 cGy) 10 6 CT26 tumor cells and 5 £ 10 5 GM-CSF secreting B78H1 cells (bystander) (2:1 ratio) was injected subcutaneously in the hind region [22] .
Cell preparation and CD11c
+ isolation from liver and spleen Livers were processed for isolation and mononuclear inWltrate was isolated as previously described [23] . Single cell suspensions of spleens were obtained as previously described [22] . DCs were isolated using CD11c MicroBeads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's protocol, with a purity of ¸90%.
Flow cytometry and BrdU studies
Single cell suspensions were labeled with mAbs according to manufacturer's protocol, and analyzed by Xow-cytometry. mAbs against mouse CD3, CD4, CD8 , CD11c, CD11b, CD19, CD25, CD45, CD45.1, CD49b, CD115, CD117, CD135, Gr-1, B220, MHCII, TER-119, Foxp3, IFN-, Ki67, BrdU and corresponding isotype controls were obtained from BD Biosciences (San Jose, CA, USA) and eBioscience (San Diego, CA, USA). AH1 423-431 /L d tetramer (AH-1 tetramer) was obtained through the National Institute of Allergy and Infectious Diseases Tetramer Facility and the National Institutes of Health AIDS Research and Reference Reagent Program (Bethesda, MD, USA). Staining was done as previously described [22] . For BrdU studies, animals were intraperitoneally injected with 1 mg of BrdU (Sigma-Aldrich, St Louis, MO, USA) on day 21 after tumor implantation and fed BrdU-containing water (0.8 mg/ml) for additional 2 days.
Adoptive transfer of monocytes
Bone marrow (BM) monocytes were isolated from BALB/ c-CD45.1 + mice using biotin-conjugated CD115 and antibiotin MicroBeads (Miltenyi Biotec), with a purity of 92-96% [24] . 10 7 of CD115 + monocytes were injected in lateral tail vein of Cy-treated or untreated tumor-bearing mice on day 16 after tumor injection.
Cytokine production assessment
Liver and splenic DCs were cultured overnight in complete medium and production of IL-12p40 and IL-10 was quantiWed using Quantikine ELISA kits (R&D systems, Minneapolis, MN, USA) following the manufacturer's protocol.
Assessment of T cell responses
Liver and splenic DCs were cultured overnight in complete medium. In designated experiments, 5 M of CpG1826 oligodeoxynucleotide was added to DCs. For mixed lymphocyte reaction, DCs were retrieved the following day, washed thoroughly and irradiated with 3,000 cGy before plating in triplicates with C57BL/6 lymph node cells. For assessment of Treg proliferative responses, naïve BALB/c CD4 +
CD25
+ T cells were sorted from pooled spleens and lymph nodes using FACSVantage (BD Biosciences) and added to hepatic or splenic DCs at a 1:1 ratio. In both assays, 1 Ci/well 3 [H] thymidine was added during the last 16 h of a 96-h incubation.
Quantitative analysis of DC gene expression Total RNA was puriWed from isolated DCs using RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) and reverse transcribed using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). cDNA was subjected to polymerase chain reaction ampliWcation using primers for 18s rRNA, IL-12p40, TNF-, MCP-1, and MIP-1 [25] [26] [27] [28] [29] , using SYBR Premix Ex Taq DNA polymerase (Takara Bio, Madison, WI, USA) and MyiQ light cycler (Bio-Rad).
Statistical analysis
Values are presented as the mean § SEM. Statistical diVerences were calculated using one-way ANOVA, MannWhitney U tests, or log-rank test, as appropriate. A value of P < 0.05 was considered to be signiWcant.
Results
Cy augments antitumor immunity and its eYcacy cannot be improved by Treg depletion
To mimic the pathophysiologic scenario of advanced malignancy, we used a CT26 hepatic metastasis model of colon cancer [23] . In initial experiments, we compared the eYcacy of the nonmyeloablative dose of TBI (200 cGy on day 10), Cy (200 mg/kg on day 13), or both modalities combined. We found, that in this model, growth of hepatic metastases was not inhibited by administering TBI alone, while treatment with Cy resulted in long-term tumor-free survival in approximately 40% of animals (Fig. 1a) . The administration of TBI prior to Cy not only failed to improve the eYcacy of treatment, but decreased the beneWcial eVect of Cy, suggesting that antitumor eYcacy of Cy cannot be explained solely by its cytotoxic activity. To conWrm that antitumor immunity can be augmented in this setting we used a strategy of administering tumor vaccine after Cy [30] . Administration of tumor vaccine comprised of irradiated CT26 cells together with GM-CSF-secreting bystander cells resulted in augmented survival and induction of long-term tumor-speciWc immunity (P < 0.05 for Cy vs. Cy followed by vaccine; Fig. 1a ).
In the next set of experiments, we used IFN-KO mice to determine if the beneWcial eVect of Cy administration was primarily due to direct cytotoxicity toward tumor cells or an active immune response. Tumor-bearing IFN-KO and wildtype BALB/c mice were treated with Cy or left untreated. Survival of tumor-bearing IFN-KO mice receiving Cy was inferior to that of identically treated wild-type BALB/c mice and similar to that of untreated IFN- KO or BALB/c controls (Fig. 1b) . The complete loss of Cy's therapeutic eVect in IFN-KO mice suggests that potent T cell IFN--mediated responses are required for successful antitumor immunity in our model.
Next, we evaluated contribution of T cell subsets to the Cy-mediated antitumor eVect. Tumor-bearing animals were injected intraperitoneally with 0.25 mg of anti-CD4, anti-CD8, or IgG 2b isotype on days 6, 10, and 12 after tumor challenge. We found that CD8, but not CD4, depletion completely abrogated the antitumor eYcacy of Cy (Fig. 1c) . Lack of Cy-mediated antitumor eVect after CD8 depletion further strengthens the previous Wnding that Cy's eVect is a result of immune response, rather than the direct killing of tumor.
The eYcacy of Cy in augmenting antitumor immunity has been mostly attributed to its eVect on elimination of regulatory CD4 + CD25 + Foxp3 + T cells. To assess whether the eVects of Cy could be augmented by further depletion of Tregs, we used a CD25-depleting antibody (PC61) known to augment antitumor immunity [31] . Tumor-bearing Cy-treated or untreated animals received anti-CD25 mAb, or IgG 1 isotype control, intraperitoneally at a dose of 0.5 mg on days 13 and 16 after tumor injection. This dose of anti-CD25 mAb induced depletion of CD25 + Tregs in spleen and liver of the tumor-bearing mice, severity and duration of which surpassed those seen with Cy treatment alone (Supplementary Figure 1) . We found that anti-CD25 treatment, whether alone, or in combination with Cy, provided no additional survival beneWt (Fig. 1d) . Collectively, these data suggest that Cy is an eVective strategy for augmenting CD8 + T cell-mediated antitumor immune response in the setting of established malignancy and that eVects of Cy in this setting extend beyond the elimination of Tregs. Cy selectively augments expansion of IFN--secreting and tumor antigen-speciWc CD8 + T cells without a lasting eVect on Tregs and NK cells Absence of additional beneWt of treating tumor-bearing mice with anti-CD25 mAb, led us to investigate the eVects of Cy on eVector arm of T cell response. Untreated and Cytreated tumor-bearing animals were analyzed on day 23 after tumor inoculation (10 days after Cy administration) and compared to naïve controls. Analysis focused on liver, representing the tumor site, and spleen, a draining secondary lymphoid tissue. Since the composition of hepatic and splenic mononuclear cell inWltrate in animals treated with surgery and intrasplenic injection of PBS did not diVer from that in naïve mice (data not shown), all subsequent experiments used naïve BALB/c mice as controls. We found that 10 days after Cy administration, livers of mice injected with Cy contained higher percentages and absolute numbers of CD8 + , but not CD4 + T cells (P < 0.05 for Cy vs. both naïve and untreated tumor-bearing animals; Fig. 2a ). The number of T cells in spleen did not diVer signiWcantly between the groups (data not shown). CD8 + T cells retrieved from the tumor bed of Cy-treated animals also secreted higher amounts of IFN-, when compared to those isolated from untreated or naïve animals (P < 0.05, Fig. 2b ). When the total numbers of CD8 + T cells were compared, the diVerence became even more prominent (Fig. 2b) . [32] . Despite Cy administration, tumor-speciWc AH-1 + CD8 + T cells that were induced by tumor presence persisted in the livers of tumorbearing hosts (Fig. 2c) . These observations suggest that the host immune system recognizes the growing tumor; however, the responding cells are restrained in their ability to promote its eradication [33] .
Despite the transient depletion of regulatory Foxp3 + CD4 + T cells that occurs early after drug treatment (data not shown), no diVerence in the pool of Tregs between Cy-treated and untreated animals was present on day 10 after Cy administration (Fig. 2d) . These results, together with ineVectiveness of PC61 mAb to further augment antitumor immunity by enhancing Treg depletion, prompted us to examine whether Cy-mediated eVects may be in part explained by its inXuence on Treg functional state. In vitro studies conducted by Lutsiak et al. showed that Tregs from Cy-treated mice exhibit transiently impaired suppressive function that returns to baseline within 10 days after drug administration [17] . To examine the Treg function in vivo we relied on recent data suggesting that functionality of Tregs is reXected in their phenotype. Tang et al. reported that Foxp3 + CD4 + T cells present at the inXammatory sites have reduced expression of CD25, a receptor for IL-2, and a critical growth factor for Tregs [34] . We found that cell surface density of CD25 (as assessed through mean Xuorescence intensity) on the liverinWltrating Foxp3 + CD4 + T cells of Cy-treated mice was signiWcantly reduced when compared with that found on Tregs in untreated tumor-bearing animals (P < 0.05; Fig. 2e ). The reduced CD25 expression on Foxp3 + CD4 + Tregs was also evident in spleens of Cy-treated and untreated tumor-bearing mice (data not shown) suggesting that the loss of CD25 expression is result of the drug treatment.
Finally, we examined the eVect of Cy on NK cells and found that drug treatment decreases the percentage of NK cells in the pool of liver-inWltrating leukocytes when compared to that in both naïve and untreated tumor-bearing mice (Fig. 2f) . This Wnding suggests that NK cells do not play a signiWcant role in augmented antitumor immunity after Cy administration.
Cy inXuences the number, phenotypic composition, and turnover of DCs in the liver of tumor-bearing mice
We hypothesized that Cy, through its myelosuppressive eVects, perturbs homeostasis and induces turnover of DCs, including those inWltrating the tumor. Cells with a DC morphology and/or expression of DC markers have been repeatedly described to inWltrate murine and human tumors, but the eVect of chemotherapy on them remains uncertain [35] . We Wrst determined the eVect of Cy on the CD11c + DCs in liver, representing tumor-inWltrating DCs (TIDCs), and found that on day 23 after tumor inoculation, both percentage of CD11c + DCs and their absolute count were higher in Cy-treated tumor-bearing animals (P < 0.005; Fig. 3a) . In general, hepatic DCs can be categorized into phenotypically and functionally distinct subpopulations, including CD8 ¡ CD11b + CD11c + , CD8 + CD11c + , B220 + CD11c int , and CD11c + DCs expressing none of these molecules [36] [37] [38] . We found that Cy administration to tumor-bearing animals induced profound changes in all three deWned liver DC subsets (P < 0.01; Fig. 3b ). The same pattern and magnitude of change were observed in spleen (data not shown).
The described changes in the TIDC pool could be a result of direct Cy-mediated functional alterations of preexisting TIDCs or Cy-mediated killing of TIDCs with subsequent de novo recruitment of DCs to the tumor site. To address this we assessed proliferation of DCs by analyzing the incorporation of BrdU and expression of Ki-67. We found that DCs retrieved from Cy-treated mice co-expressed BrdU and Ki67 at signiWcantly higher levels than those from tumor-bearing untreated animals (P < 0.005; Fig. 3c, d ). The increase in BrdU incorporation in Cy-treated animals was observed for all subtypes of conventional splenic and hepatic DCs (Supplementary Figure 2) . Conventional spleen DCs (cDCs) are considered to emerge from the BM precursors as immature cells that must further diVerentiate and divide in lymphoid organs [39] . Under steady-state conditions, the rate of cDC division is regulated by Flt3 (CD135) receptor signaling, as recently shown using BrdU incorporation and CFSE dilution methods [40] . Whether the observed proliferation of cDCs is result of Cy-induced CD135 receptor signaling or some other mechanisms would need to be determined in future studies. Nonetheless, these results support our hypothesis that through myelosuppression-mediated mechanisms Cy directly inXuences DC homeostasis and induces their turnover in tumor-bearing host.
Cy induces DC turnover by preferentially recruiting early DC progenitors
It has been suggested that CD135 + DC progenitors and Gr-1 hi monocytes are endowed with immediate DC precursor potential [41] . Since Cy is known to induce myelomonocytosis [42] , we examined Wrst whether the observed increase in tissue DCs is a result of monocyte diVerentiation. In assessing Cy's eVect we found that in naïve (Fig. 4a) and tumor-bearing animals (data not shown), Cy rapidly eliminated circulating monocytes. However, starting on day 4, monocytes began their recovery surge and on day 5 achieved peak levels that were tenfold higher than in steady-state, followed by rapid return to pre-treatment levels by day 10. To track their DC-diVerentiation potential, we adoptively transferred BM-derived monocytes that diVered from the host in the expression of CD45 allele. In sorting monocytes for adoptive transfer we relied on their expression of CD115 + , a receptor for colony-stimulating factor 1. Isolated CD115 + monocytes from BALB/c-CD45.1 + mice were transferred to Cy-treated or -untreated tumor-bearing wild-type BALB/c (CD45.2 + ) mice on day 16 (day 3 after Cy treatment and point of maximal monocyte nadir). Surprisingly, we found that on day 23 a signiWcantly higher percentage of monocyte-derived DCs was present in liver and spleen of untreated vs. Cy-treated mice (P < 0.01; Fig. 4b ). CD45.1 + -derived DCs in both organs expressed intermediate levels of CD11c (data not shown), which is consistent with their monocytic origin [43] . Additional analysis revealed that, regardless of Cy administration, monocyte-derived DCs had unrestricted maturation potential as evidenced by expression of high levels of MHC class II (data not shown).
Dendritic cell homeostasis in steady-state is dependent on the rate of DC progenitor input from blood, cell division, and cell death. Recruitment of DCs to both normal and malignant tissues is the result of their response to various chemokines. We focused on MCP-1 and MIP-1 , two chemokines known to be critical for recruitment of DCs. Both chemokines are secreted by liver DCs [44] , but the expression of MCP-1 is associated with monocyte recruitment [45] while MIP-1 plays a role in recruitment and proliferation of DC precursor populations in vivo [46, 47] . We found that hepatic CD11c + DCs isolated from untreated tumor-bearing mice expressed mRNA for MCP-1 at higher levels than those from Cy-treated animals. In contrast, CD11c + DCs from Cy-treated tumor-bearing animals predominantly transcribed MIP-1 (Fig. 4c) .
Since that includes primitive HSCs and/or multipotent progenitors (Fig. 4d) . This increase in circulating HSCs was result of increased numbers of these cells in the BM of Cy-treated animals (data not shown). This prompted us to examine the recently identiWed common DC precursors (CDPs) [48] (Fig. 4e, f) . Moreover, we found an increase in the CDPs in both spleen and liver of Cy-treated tumor-bearing animals on day 23 after tumor injection (Fig. 4g) Overall, these results suggest that tumor milieu promotes increased accumulation of monocytes, rather than DCs, and that in Cy-treated tumor-bearing host recruited DCs originate from mobilized early DC progenitors. This, to our knowledge, is the Wrst demonstration of drug treatmentinduced recruitment of early DC progenitors; however, it is not entirely surprising considering the stem cell mobilization properties of Cy. Cytokine-secretion patterns and functional characteristics of tumor-inWltrating DCs are inXuenced by Cy Next, we analyzed the functional ability TIDCs to prime T cell responses. We found that DCs retrieved from the Cy-treated tumor-bearing animals expressed mRNA for proinXammatory cytokines TNF-and IL-12p40 at higher levels than tumor-bearing untreated mice (Fig. 5a) . Furthermore, DCs isolated from livers of Cy-treated tumor-bearing mice secreted 16-fold higher amounts of IL-12p40, as assayed by ELISA (P < 0.005, Fig. 5b ). In contrast, DCs isolated from untreated animals produced sixfold higher amounts of IL-10 (P < 0.0001, Fig. 5b ) a known immunosuppressive cytokine. Similar patterns were observed in the spleen, suggesting that Cy treatment has a direct proinXammatory eVect on both tumor-inWltrating (liver) and systemic (spleen) DCs. + DCs were retrieved from Cy-treated and untreated tumor-bearing animals and cultured with freshly isolated BALB/c CD4 + CD25 + T cells. Indeed, DCs isolated from livers of Cy-treated mice were ineVective in inducing proliferation of CD4 + CD25 + T cells in contrast to those isolated from tumor-bearing untreated animals (P < 0.05, Fig. 5c ). However, these results were not observed with splenic DCs (data not shown), suggesting that DCs in Cy-treated mice are less inXuenced by intratumor Tregs and may be more eVective in inducing in situ antitumor immune responses. Previous observations also suggested that TIDCs are functionally paralyzed due to the presence of inhibitory signals such as IL-10 and TGF-in the tumor milieu [51, 52] . To determine the eVect of Cy on functional characteristics of DCs, we assessed their ability to prime de novo immune responses in a mixed leukocyte reaction-type assay. Hepatic and splenic CD11c + DCs isolated from Cy-treated and untreated tumor-bearing animals were cocultured with C57BL/6 T cells and proliferation of allogeneic T cells was assessed 72 h later. We found that DCs isolated from livers of Cy-treated tumor-bearing mice induced a prominent proliferation of allogeneic T cells in contrast to DCs isolated from the livers of untreated tumor-bearing mice (Fig. 5d) . In addition, CpG stimulation of both hepatic and splenic DCs isolated from tumor-bearing mice had no eVect on their ability to stimulate allogeneic T cells, whereas a prominent eVect was induced by CpGs on DCs from Cytreated mice (Fig. 5d, e) . A similar lack of DC activation was observed if DCs from tumor-bearing animals were stimulated with anti-CD40 or a combination of CpG1826 and anti-CD40 (data not shown).
In conclusion, these data are consistent with studies showing that TIDCs are refractory to ex vivo maturation stimuli and may be in a state of functional paralysis in vivo [52] , but also imply that Cy-induced DCs carry a more proinXammatory proWle, are released from inXuence of immunoregulatory networks, and capable of initiating de novo immune responses.
Discussion
The results of this study highlight a novel Wnding that Cy, a well characterized and widely used chemotherapeutic agent, can inXuence antitumor immunity, not only through direct eVects on T cells, but also by aVecting the DC homeostasis in the tumor-bearing host. We found that Cymediated antitumor immunity in the setting of pre-established malignancy is predominantly mediated by CD8 + T cells and that despite transient removal of Tregs Cy's eVect cannot be further augmented with CD25 + Treg depletion. Additionally, we observed that Cy administration, through myelosuppression and rebound reconstitution of myelopoiesis, leads to reversal of systemic and in situ tumor-induced DC paralysis. Moreover, Cy-mobilized proliferating early DC progenitors to the tumor site where they yielded new DCs. Therefore, similar to the lymphodepleting paradigm, the post myelosuppressive environment may be advantageous for development of antitumor immunity.
In contrast to studies showing Cy-mediated antitumor immunity to be a primary function of Treg elimination, we found that although Tregs are depleted after Cy treatment, they rapidly reconstitute both secondary lymphoid tissues and tumor site. The rapid repopulation of Treg compartment after Cy-induced perturbation is likely a result of a TGF--abundant environment in tumor-bearing hosts that provides a stealthy impetus for a rapid Treg proliferation [51] . Still, prolonged CD25 depletion in the post-Cy setting provided no added beneWt to the Cy treatment alone. This Wnding, although somewhat surprising, is consistent with published studies in which this strategy has not enhanced other immunomodulatory approaches in the setting of established malignancy [53] [54] [55] . Clinical studies using the Treg-directed strategies such as a CD25-directed immunotoxin (LMB-2) or recombinant IL-2 fused to diphtheria toxin (ONTAK) failed to report any signiWcant clinical responses despite showing decrease in the number of Tregs in peripheral blood and heightened antitumor T cell responses in vitro [56, 57] . On the other hand, as recently demonstrated, adoptive transfer of puriWed CD25 + Tregs into Cy-treated mice directly negates the curative property of the drug [55] . However, ineVectiveness of CD25-depletion in the same model of pre-established mesothelioma strongly implied the importance of other mechanisms by which Cy augments T cell-mediated antitumor immunity.
Several Wndings of this study are relevant for understanding multifaceted mechanisms behind Cy's beneWcial eVects on augmenting antitumor immunity. First, Cy, through its myelosuppressive action, eliminates TIDCs, mobilizes early DC precursors that through their rapid proliferation in periphery increase the presence of new APCs that can prime de novo T cell responses. This is supported by high expression of Ki-67 in cDCs and increase in Lin Current strategies to modulate in vivo DCs in the tumorbearing host are mostly focused on their activation and/or reversal of their functional paralysis rather than modulating their in vivo homeostasis [52, 58] . In this regard, eVects of Cy are unique since through myelosuppressive eVects on TIDCs and mobilization of early DC progenitors it directly inXuences the DC homeostasis in tumor-bearing host. What the contribution of MDPs and CDPs is to DC pool and augmenting of T cell-mediated antitumor immunity remains to be determined. These studies would require the use of CX 3 CR1-gfp + mice which would provide additional advantage of the ease of sorting these early DC precursors for functional in vivo studies. Second, Cy, besides transient quantitative depletion of Tregs may also have an eVect on their in vivo function. Lutsiak et al. have shown that Cy administration leads to the loss of their suppressor functionality as assessed in vitro [17] . We found that Foxp3 + CD4 + Tregs retrieved from Cy-treated tumor-bearing mice express lower amounts of CD25, a receptor for IL-2, a critical Treg growth factor. Reduced expression of CD25 on Foxp3 + CD4 + Tregs has been associated with local loss of Treg:eVector T cell balance and correlates with a heightened immune response [34] . Further characterization of Tregs persisting in tumor-bearing host after Cy administration and why their additional elimination with PC61 mAb does not augment antitumor immunity is required. Finally, Cy through the induction of immunogenic cell death leads to increased phagocytosis of apoptotic tumor cells by DCs leading subsequently to their activation (Supplementary Figure 3) . These eVects of Cy, coupled with drug's sparing eVects on pre-existing tumor-speciWc CD8 + T cells may be essential for observed unleashing of antitumor immunity after drug administration. Thus, Cy has a direct impact on DC-T cell interactions in tumor-bearing host that ultimately lead to a better priming of tumor-speciWc T cells. These observations augment the notion that mobilization of early DC precursors to the site of ongoing immune response and their diVerentiation into DCs can lead to optimal T cell priming [39, 46] . Cy, thus, through its unique ability to mobilize DC precursors can inXuence the DC homeostasis both in situ and systemically.
In conclusion, previous studies have suggested that beneWcial eVects of Cy in augmenting antitumor immunity are primarily a result of drug's ability to eliminate Tregs and/or augment the homeostasis-driven expansion of pre-existing tumor-speciWc eVector T cells [7] [8] [9] . Our study provides a novel observation that Cy inXuences antitumor immune responses by resetting the DC homeostasis in tumor-bearing host.
